Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere's Disease

SAN DIEGO, Nov. 18, 2015 -- (Healthcare Sales & Marketing Network) -- Otonomy, Inc. (OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today ... BiopharmaceuticalsOtonomy, OTO-104, Meniere's Disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news